%0 Journal Article
%T SYL3C aptamer-anchored microemulsion co-loading ¦Â-elemene and PTX enhances the treatment of colorectal cancer
%A Chuanpei Cao
%A Nan Li
%A Shaofei Yuan
%A Xiaorong Zhou
%J Drug Delivery
%D 2019
%R https://doi.org/10.1080/10717544.2019.1660733
%X Abstract The aim of this study is to construct a SYL3C aptamer-anchored microemulsion based on ¦Â-elemene and PTX (SYL3C/EP-MEs) for enhancement on colorectal cancer therapy. Such microemulsion is consist of encapsulated drugs (¦Â-elemene and PTX), tumor targeting ligand (3¡¯-end thiolated SYL3C aptamer), thiol conjugated site (maleimide-modified PEGylated 1,2-dioleoyl-sn-glycero-3-phosphoethanolamine, mal-DOPE-PEG), pH-sensitive component (DOPE) and other necessary excipients. SYL3C/EP-MEs showed a spherical particle with an average particle size around 30£¿nm and a high encapsulation efficiency (>80%) for both drugs. ¦Â-elemene and PTX could be released controllably from SYL3C/EP-MEs as pH values changed. SYL3C/EP-MEs displayed a selective affinity to HT-29 cells, leading to an obvious increase in cellular uptake, cell apoptosis and cytotoxicity. In the HT-29 tumor xenograft-bearing nude mice model studies, SYL3C/EP-MEs showed an overwhelming tumor growth inhibition, the longest survival time and the lowest systemic toxicity among all the treatments. The potential mechanism of enhanced anti-cancer ability was probably associated with the induction of M1 macrophage polarization, the downregulation of mutant p53 protein and the reduction of bcl-2 protein expression. Collectively, the microemulsion codelivery of ¦Â-elemene and PTX using functionalization with SYL3C aptamer provides a novel approach for combinational colorectal cancer-targeted treatment
%U https://www.tandfonline.com/doi/full/10.1080/10717544.2019.1660733